Publications
Publications on tele-ophthalmic support improving anti-VEGF outcomes (Münster "Portal").
2020-2023 DOC Management in Clinic and Practice | Mussinghoff | Telemonitoring using the example of the IVI Portal in Münster.
Stable visual acuity (VA) over 2 years in IVI Portal Münster compared to other real-world studies like AURA with below-baseline VA
Persistence over 2 years in IVI Portal Münster, 2x higher compared to other real-world studies like PERSEUS and AURA (<0.4)
Selected publications by leading scientists on how AI can provide a 2nd opinion for anti-VEGF therapy.
2023 EURETINA | Gutfleisch et al. | A Post Hoc Analysis of intravitreal aflibercept–treated nAMD Patients from ARIES & ALTAIR: Predicting Patient-Individualized Treatment Interval for aflibercept Treat-And-Extend Therapy Regimen by Adapting AI Algorithms Trained on Pro-Re-Nata Data
2022 DOG PFr05-05 | Gutfleisch et al. | Annotation of SD-OCT biomarkers in nAMD for the development of explainable AI models (XAI).
2023 DOG PDo04-05 | Gutfleisch et al. | Validation of an AI algorithm for detection and grading of SD-OCT biomarkers in neovascular AMD (nvAMD) using an external real-life data set
2022 DOG PDo04-11 | Rothaus et al. | Predicting the need for therapy in neovascular AMD (nAMD) using annotation-based deep learning models.
2023 EVER | Assaf et al. | Detection of Subretinal and Intraretinal Fluids in Optopol SD-OCT Using Transfer Learning
You Want to Get Involved in AI, too?
Watch replays of public talks by us
2022 Oracles of Eye Innovation Webinar XII
2023 Talk at Deutsches Museum (German only)
Autumn Lang, Ph.D., RAC, Director Clinical Affairs
Anything missing?
Should we not have what you are looking for, we are happy to point you to other studies without our involvement. In any case, reach out to us! suggest changing to: Reach out to us, we welcome the opportunity to collaborate and refer you to any relevant studies (even those outside of our own studies)!